Dhanapalan Nagarathnam's Email & Phone - NorthEast BioLab

Dhanapalan Nagarathnam's Work Experience

NorthEast BioLab

VP, Drug Discovery

Hamden, Connecticut

Synaptic Pharmaceutical Corporation

Principal/Senior Research Scientist

June 1993 to December 1998

DNSK International, LLC.

President and CEO

Hamden, CT 06514

Dhanapalan Nagarathnam's Education

University of Illinois at Chicago

Postdoctoral, Medicinal Chemistry, Drug design and synthesis, computer modeling

2001 to 2003

Purdue University

Postdoctoral, Medicinal Chemistry

1999 to 2001

University of California, Davis

Research Associate, Bioorganic and Medicinal Chemistry

1998 to 1999

Dhanapalan Nagarathnam's Professional Skills Radar Chart

Based on our findings, Dhanapalan Nagarathnam is ...

Measured

Vivacious

Purposeful

What's on Dhanapalan Nagarathnam's mind?

Based on our findings, Dhanapalan Nagarathnam is ...

57% Left Brained

43% Right Brained

Dhanapalan Nagarathnam's Estimated Salary Range

About Dhanapalan Nagarathnam's Current Company

NorthEast BioLab

Frequently Asked Questions about Dhanapalan Nagarathnam

What company does Dhanapalan Nagarathnam work for?

Dhanapalan Nagarathnam works for NorthEast BioLab

What is Dhanapalan Nagarathnam's role at NorthEast BioLab?

Dhanapalan Nagarathnam is VP, Drug Discovery

What is Dhanapalan Nagarathnam's personal email address?

Dhanapalan Nagarathnam's personal email address is d****[email protected]

What is Dhanapalan Nagarathnam's business email address?

Dhanapalan Nagarathnam's business email addresses are not available

What is Dhanapalan Nagarathnam's Phone Number?

Dhanapalan Nagarathnam's phone (203) ***-*397

What industry does Dhanapalan Nagarathnam work in?

Dhanapalan Nagarathnam works in the Biotechnology industry.

About Dhanapalan Nagarathnam

📖 Summary

VP, Drug Discovery @ NorthEast BioLab Hamden, ConnecticutPrincipal/Senior Research Scientist @ Synaptic Pharmaceutical Corporation GPCR antagonists, agonists, produced sub-nanomolar leads, very selective compounds with good PK and safety profile. Lead generation and optimization. Worked on multiple chemical classes of heterocyclic compounds. From June 1993 to December 1998 (5 years 7 months) President and CEO @ DNSK International, LLC. Collaborative drug discovery with biotechs, pharmaceutical companies and universities in multiple therapeutic areas, including oncology, immunology, diabetes, virology, anti-infectives, inflammatory bowl diseases, etc.Our first and major collaboration is with Rhizen Pharmaceuticals, Switzerland.Multiple compounds in human clinical trials. Most advanced product: TGR-1202 (Umbralisib), RP5264 best-in-class PI3K delta selective inhibitor in Phase-3 trials to treat Chronic Lymphocytic Leukemia (CLL). For more details, please check athttp://www.tgtherapeutics.com/pipeline/TGR-1202.cfmhttp://www.rhizen.com/otxpipleine.htmlSecond Product - RP6530, Best-in-class PI3K delta/gamma dual selective inhibitor that has completed Phase 1 trials. More details at http://www.rhizen.com/otxpipleine.htmlSpecialties: Drug discovery, Project Leader/Manager, Intellectual Property and Patent Applications, Competitive Intelligence, Due Diligence, Mentor/Trainer, Medicinal Chemistry, Synthetic Organic Chemistry, Parallel Synthesis, Lead Generation, Efficient Lead Optimization, Best-in-class Clinical Candidates, Process Research, Manufacturing, Optimized Drug Substance, Targeted Drug Discovery, CMC, Business Development, Global Collaborative Research and Drug Discovery, Oral, Inhaled, IV Drug Design, Structure/Fragment Based Drug Design, HCV, Oncology, Inflammation, BPH, Pain, Diabetes, Obesity, Anti-infectives, Ulcerative Colitis, Stem Cells, Respiratory, Kinase Inhibitors, Cytotoxic Agents, Polymerase Inhibitors, Protease Inhibitors, GPCR Antagonists/Agonists, Nuclear Hormone Receptors. Multi-step total synthesis of complex molecules, Peptides, Peptidomimetics, etc.With these experiences, I would be happy to collaborate and work on many more Drug Discovery Projects to find innovative and high quality clinical candidates..Collaborative projects with the University of West Virginia, University of Chicago, University of Illinois at Chicago, etc. Hamden, CT 06514Vice President and Co-founder @ DNSK International, LLC. Project Management with multiple international outsourcing companies.Creation/Identification of New Drug Discovery Projects. Lead Generation, Lead Optimization, Generation Preclinical Candidates, Process Research, Metabolite ID and synthesis.Consultation on improving the quality of candidates, research on follow-up candidates. Director, Medicinal Chemistry @ Pharmasset, Inc. Synthesis of nucleoside prodrugs for the treatment of HCV. Discovery and development of antiviral agents. Directed the Medicinal Chemistry of the HCV drug discovery portfolio and played key role in nominating nucleoside prodrugs, Co-authored in multiple presentations/publications/patents/patent applications from this HCV research work. From 2007 to June 2009 (2 years) Principal Research Scientist II @ Bayer Health Care Medicinal Chemistry, Kinase Inhibitors - broad spectrum and selective, Novel Cell Cycle Inhibitors, High-Speed Synthesis, Novel Lead Generation, Lead Optimization, Cancer, Diabetes, Obesity, Contributed to optimization of leads to NCEs.Initiated the Chemistry effort on the early research project of the recently approved drug Aliqopa (copanlisib) to treat patients with relapsed follicular lymphoma. From January 1999 to January 2007 (8 years 1 month)

Dhanapalan Nagarathnam’s Personal Email Address, Business Email, and Phone Number

are curated by ContactOut on this page.

10x your recruitment & sales conversations

Contact over 200M professionals
instantly by email or phone. Reveal
personal & work email addresses, as
well as phone numbers accurately with
our ContactOut Chrome extension.

In a nutshell

Dhanapalan Nagarathnam's Personality Type

Extraversion (E), Intuition (N), Thinking (T), Judging (J)

Average Tenure

5 year(s), 2 month(s)

Dhanapalan Nagarathnam's Willingness to Change Jobs

Unlikely

Likely

Open to opportunity?

There's 87% chance that Dhanapalan Nagarathnam is seeking for new opportunities